DBV Technologies (NASDAQ:DBVT) Price Target Raised to $55.00

DBV Technologies (NASDAQ:DBVT) had its target price raised by stock analysts at Citizens Jmp from $47.00 to $55.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s price objective would suggest a potential upside of 242.25% from the company’s previous close.

A number of other equities research analysts have also issued reports on DBVT. Guggenheim reissued a “buy” rating and issued a $51.00 target price on shares of DBV Technologies in a research report on Monday, May 4th. Wall Street Zen raised DBV Technologies from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. Finally, Citigroup reissued an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, DBV Technologies presently has an average rating of “Moderate Buy” and a consensus price target of $48.50.

DBV Technologies Stock Performance

Shares of DBVT stock traded up $0.07 during mid-day trading on Tuesday, reaching $16.07. The company’s stock had a trading volume of 71,803 shares, compared to its average volume of 298,517. DBV Technologies has a 1-year low of $8.51 and a 1-year high of $26.18. The firm’s 50-day moving average is $18.33 and its two-hundred day moving average is $19.86. The company has a market cap of $951.50 million, a P/E ratio of -3.60 and a beta of -0.99.

DBV Technologies (NASDAQ:DBVT) last announced its earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%.The firm had revenue of $0.90 million for the quarter, compared to analyst estimates of $1.11 million. Sell-side analysts anticipate that DBV Technologies will post -0.47 EPS for the current year.

Institutional Investors Weigh In On DBV Technologies

Hedge funds have recently made changes to their positions in the company. UBS Group AG raised its holdings in shares of DBV Technologies by 165,347.3% during the fourth quarter. UBS Group AG now owns 244,862 shares of the company’s stock valued at $4,694,000 after purchasing an additional 244,714 shares during the last quarter. DLD Asset Management LP bought a new position in shares of DBV Technologies during the 3rd quarter worth $250,000. Polymer Capital Management HK LTD purchased a new stake in shares of DBV Technologies during the 4th quarter worth $1,236,000. Allworth Financial LP purchased a new stake in DBV Technologies in the fourth quarter valued at about $32,000. Finally, GAMMA Investing LLC lifted its position in DBV Technologies by 38.4% during the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after acquiring an additional 744 shares during the period. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.